Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.
The FDA has granted priority review status for atezolizumab, a drug that treats locally advanced or metastatic non-small cell lung cancer (NSCLC) expressing the PD-L1 protein.
Atezolizumab was previously granted Breakthrough Therapy Designation for NSCLC in February 2015, and was previously granted priority review for a different type of cancer.
On March 14, 2016, atezolizumab was granted priority status for locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-based chemotherapy in the metastatic setting, or whose disease progressed within 12 months of receiving platinum-based chemotherapy before surgery or after surgery.
The NSCLC Biologics License Application submission was based on results from several clinical trials, including the open-label, multicenter, single-arm phase 2 BIRCH study.
The study enrolled 667 patients with locally advanced or metastatic NSCLC that expressed PD-L1 to test the safety and efficacy of atezolizumab. Participants were administered 1200-mg of atezolizumab intravenously, every 3 weeks.
Throughout the trial, researchers used an IHC test to assess PD-L1 expression for both tumor cells and tumor-infiltrating immune cells, based on the SP142 antibody.
“In a study of atezolizumab in people with previously treated advanced lung cancer, PD-L1 expression correlated with how well they responded to the medicine,” said Sandra Horning, MD, Genentech chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to benefit from atezolizumab alone.”